RELMADA THERAPEUTICS INC (RLMD)
Health Care · NASDAQ
Clinical-stage biotech redirecting toward oncology and neurology with in-licensed chemotherapy delivery and neurosteroid platforms after terminating its lead depression candidate.
What RELMADA THERAPEUTICS INC does
Relmada Therapeutics is a clinical-stage biotechnology company that recently underwent strategic repositioning away from its original REL-1017 esmethadone program for depression. The company now focuses on two main platforms: NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel for non-muscle-invasive bladder cancer (NMIBC) currently in Phase 2 trials, and sepranolone, a neurosteroid acquired from Asarina Pharma for potential treatment of Prader-Willi syndrome, Tourette Syndrome, and essential tremor. Relmada leverages its clinical operations capabilities to advance these licensed-in candidates toward late-stage development.
Themes: []
Fundamentals
- Price$6.51 as of 2026-07-09 close
- Market cap$682M as of 2026-07-10
- 1-year return+963.2% as of 2026-07-09 close
- Net margin-500.0% as of 2026-07-10
- Gross margin+0.0% as of 2026-07-10
- ROE-71.2% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta0.46 as of 2026-07-10
Key risks (from latest filing)
[]
Competitors & peers
- Astellas Pharma (intravesical oncology therapies)
- Cepheid (BCG alternatives and NMIBC treatments)
- Janssen Pharmaceuticals (bladder cancer therapeutics)
- Neurochem Inc. (neurosteroid-based therapeutics)
- Non-muscle-invasive bladder cancer patients
- Prader-Willi syndrome patients
- Essential tremor and Tourette Syndrome patients
- Clinical-stage oncology and neurology therapeutics
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.